R&D channel feed

So close, yet so far: Zo­genix LGS tri­al suc­ceeds, but re­sults un­der­whelm

6 years ago

Gilead los­es key patent chal­lenge over best-sell­ing HIV drug

6 years ago

Ian Read adds a new post to his grow­ing ros­ter of post-Pfiz­er po­si­tions — and this one pays well

6 years ago
People

Roche/PTC edge clos­er to dis­rupt­ing mar­ket for SMA ri­vals Bio­gen and No­var­tis with more pos­i­tive da­ta

6 years ago

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

6 years ago
Cell/Gene Tx

GSK’s vac­cines group — in­clud­ing R&D — faces heavy job cuts in lat­est re­struc­tur­ing

6 years ago

Jef­frey Blue­stone ex­its Park­er and switch­es fo­cus back to au­toim­mune dis­eases in cell ther­a­py 2.0 launch

6 years ago

Sanofi's R&D group spot­lights a big win for BT­Ki mul­ti­ple scle­ro­sis drug. But plen­ty of ques­tions re­main

6 years ago

Nestlé puts $200M more be­hind a treat­ment for peanut al­ler­gy

6 years ago

Bill Gates pitch­es in on coro­n­avirus R&D and con­tain­ment ef­forts with $100M com­mit­ment

6 years ago
Coronavirus

EMA, FDA and WHO prep for new coro­n­avirus treat­ments, IVDs

6 years ago
FDA+
Coronavirus

Ac­tive Biotech is back, with one last bid for the failed MS drug Te­va dis­card­ed

6 years ago

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

6 years ago
Deals
Pharma

Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

6 years ago

Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

6 years ago
Bioregnum
Opinion

HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

6 years ago

Bio­Mo­tiv, Bris­tol-My­ers al­liance bears fruit with new com­pa­ny: An­teros Phar­ma

6 years ago
Deals

Re­gen­eron joins the hunt for an­ti­bod­ies to fight a brew­ing pan­dem­ic as re­searchers whip up new tri­als for an­tivi­rals

6 years ago

In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

6 years ago

Failed piv­otal study? You can still have break­through ther­a­py sta­tus — FDA sig­nals to Resver­logix

6 years ago

Unit­ed Ther­a­peu­tic­s' drug fails PhII/III can­cer tri­al, mark­ing their sec­ond straight stum­ble in post-Re­mod­ulin PAH

6 years ago

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

6 years ago

Bris­tol-My­ers with­draws Op­di­vo/Yer­voy lung can­cer EU ap­pli­ca­tion — but oth­ers are in­com­ing

6 years ago

Out­go­ing CEO Jeff Lei­den takes vic­to­ry lap as Ver­tex's Trikaf­ta stuns Wall Street

6 years ago
Pharma
First page Previous page 212213214215216217218 Next page Last page
A service from the Financial Times